off
Court sides against FDA in “off-label” drug promotion case
In 2013, the FDA cancelled a special protocol assessment (SPA) for the ANCHOR trial with regard to Amarin’s request to expand the drug’s use among adults having high triglycerides with mixed dyslipidaemia.
Posted On Aug 08 2015
